OnKure Therapeutics (NASDAQ:OKUR) Raised to Sell at Wall Street Zen

OnKure Therapeutics (NASDAQ:OKUR) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research report issued on Saturday.

Other equities research analysts have also issued reports about the stock. Zacks Research lowered shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Weiss Ratings restated a “sell (e+)” rating on shares of OnKure Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and issued a $34.00 price objective on shares of OnKure Therapeutics in a report on Tuesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, OnKure Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.33.

OnKure Therapeutics Stock Performance

Shares of OKUR opened at $3.39 on Friday. The firm has a market cap of $45.87 million, a price-to-earnings ratio of -0.71 and a beta of 0.46. OnKure Therapeutics has a fifty-two week low of $1.70 and a fifty-two week high of $17.76. The firm has a 50 day moving average price of $2.81 and a 200-day moving average price of $2.56.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.09. As a group, equities research analysts predict that OnKure Therapeutics will post -4.05 earnings per share for the current year.

Institutional Investors Weigh In On OnKure Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC bought a new stake in OnKure Therapeutics during the 1st quarter valued at $43,000. XTX Topco Ltd purchased a new position in OnKure Therapeutics during the 2nd quarter valued at $25,000. Bailard Inc. purchased a new position in OnKure Therapeutics during the 2nd quarter valued at $34,000. Rangeley Capital LLC purchased a new position in OnKure Therapeutics during the 2nd quarter valued at $71,000. Finally, Highbridge Capital Management LLC increased its position in OnKure Therapeutics by 51.2% during the 2nd quarter. Highbridge Capital Management LLC now owns 663,607 shares of the company’s stock valued at $1,586,000 after purchasing an additional 224,810 shares during the period. 90.98% of the stock is currently owned by institutional investors.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.